{"pmid":32498938,"title":"Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Espanola de Ginecologia y Obstetricia and Sociedad Espanola de Trombosis y Hemostasia.","text":["Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Espanola de Ginecologia y Obstetricia and Sociedad Espanola de Trombosis y Hemostasia.","COVID-19 is associated with a systemic inflammatory response with activation of coagulation in symptomatic patients. The possibility of coagulopathies in peri- and postmenopausal women taking estrogen therapies makes it necessary to consider antithrombotic strategies, such as the use of low molecular weight heparins (LMWH) at specific prophylactic or treatment doses for each individual case, depending on the risk factors that each woman presents. For such reasons, a panel of experts from various Spanish scientific societies has met to develop usage recommendations for managing menopausal women taking menopausal hormone therapy (MHT) or combined hormonal contraception (CHC) during the COVID-19 pandemic.","Maturitas","Ramirez, Isabel","De la Viuda, Esther","Baquedano, Laura","Coronado, Pluvio","Llaneza, Placido","Mendoza, Nicolas","Otero, Borja","Sanchez, Sonia","Cancelo, M feminine Jesus","Paramo, Jose Antonio","Cano, Antonio","32498938"],"abstract":["COVID-19 is associated with a systemic inflammatory response with activation of coagulation in symptomatic patients. The possibility of coagulopathies in peri- and postmenopausal women taking estrogen therapies makes it necessary to consider antithrombotic strategies, such as the use of low molecular weight heparins (LMWH) at specific prophylactic or treatment doses for each individual case, depending on the risk factors that each woman presents. For such reasons, a panel of experts from various Spanish scientific societies has met to develop usage recommendations for managing menopausal women taking menopausal hormone therapy (MHT) or combined hormonal contraception (CHC) during the COVID-19 pandemic."],"journal":"Maturitas","authors":["Ramirez, Isabel","De la Viuda, Esther","Baquedano, Laura","Coronado, Pluvio","Llaneza, Placido","Mendoza, Nicolas","Otero, Borja","Sanchez, Sonia","Cancelo, M feminine Jesus","Paramo, Jose Antonio","Cano, Antonio"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32498938","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.maturitas.2020.04.019","keywords":["covid-19","hormone menopause therapy","venous thromboembolism prophylaxis"],"locations":["Spanish"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"e_drugs":["Heparin, Low-Molecular-Weight"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1668804508920053760,"score":9.490897,"similar":[{"pmid":32436739,"title":"Contraception during Coronavirus-Covid 19 pandemia. Recommendations of the Board of the Italian Society of Contraception.","text":["Contraception during Coronavirus-Covid 19 pandemia. Recommendations of the Board of the Italian Society of Contraception.","Purpose: The Italian Society of Contraception identified as one of its priorities the need to give recommendations on management of contraception during Coronavirus-Covid 19 pandemiaMaterials and methods: A concise communication was produced which summarises in an easy-to-read format suitable for clinicians the management of the different contraceptives mostly used. Information how to manage contraception in different conditions is presented.Results: Women may, in general, continue to use either intrauterine and or hormonal contraceptives. The use of condom should be added to any hormonal contraceptive, when the contraceptive efficacy is reduced or when women stop the contraceptive method.Conclusion: At the present time, during the Coronavirus-Covid 19 pandemia, no data contraindicate the use of intrauterine or hormonal contraceptives. Conversely the use of an appropriate contraception is advocate to prevent unintended pregnancies.","Eur J Contracept Reprod Health Care","Fruzzetti, F","Cagnacci, A","Primiero, F","De Leo, V","Bastianelli, C","Bruni, V","Caruso, S","Di Carlo, C","Farris, M","Grandi, G","Grasso, A","Guida, M","Meriggiola, M","Paoletti, A M","Cianci, A","Nappi, C","Volpe, A","32436739"],"abstract":["Purpose: The Italian Society of Contraception identified as one of its priorities the need to give recommendations on management of contraception during Coronavirus-Covid 19 pandemiaMaterials and methods: A concise communication was produced which summarises in an easy-to-read format suitable for clinicians the management of the different contraceptives mostly used. Information how to manage contraception in different conditions is presented.Results: Women may, in general, continue to use either intrauterine and or hormonal contraceptives. The use of condom should be added to any hormonal contraceptive, when the contraceptive efficacy is reduced or when women stop the contraceptive method.Conclusion: At the present time, during the Coronavirus-Covid 19 pandemia, no data contraindicate the use of intrauterine or hormonal contraceptives. Conversely the use of an appropriate contraception is advocate to prevent unintended pregnancies."],"journal":"Eur J Contracept Reprod Health Care","authors":["Fruzzetti, F","Cagnacci, A","Primiero, F","De Leo, V","Bastianelli, C","Bruni, V","Caruso, S","Di Carlo, C","Farris, M","Grandi, G","Grasso, A","Guida, M","Meriggiola, M","Paoletti, A M","Cianci, A","Nappi, C","Volpe, A"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32436739","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/13625187.2020.1766016","keywords":["covid-19","hormonal contraceptives","condom","intrauterine contraception"],"topics":["Prevention"],"weight":1,"_version_":1667521393771675648,"score":284.6962},{"pmid":32469251,"title":"The gendered impact of coronavirus disease (COVID-19): do estrogens play a role?","text":["The gendered impact of coronavirus disease (COVID-19): do estrogens play a role?","Objective: Although sex-disaggregated data for COVID-19 show equal numbers of cases between men and women, there seem to be sex differences in mortality rate and vulnerability to the disease: more men than women are dying. Methods: We have explored the potential role of estrogens in this COVID-19 gendered impact. Results: Estrogens stimulate the humoral response to viral infections, while testosterone and progesterone give an immune suppression of both innate and cell-mediated immune responses. We hypothesise that estrogens, in particular estradiol but also synthetic estrogen such as ethinylestradiol, could protect women from the most serious complications of COVID-19. The use of medications that keep hormonal levels high and stable, such as combined hormonal contraceptive, could therefore play a protective role. These potential benefits overtake the thrombotic risk in healthy women. As stated by the World Health Organization, all modern methods of contraception were safe to use during the COVID-19 pandemic.","Eur J Contracept Reprod Health Care","Grandi, Giovanni","Facchinetti, Fabio","Bitzer, Johannes","32469251"],"abstract":["Objective: Although sex-disaggregated data for COVID-19 show equal numbers of cases between men and women, there seem to be sex differences in mortality rate and vulnerability to the disease: more men than women are dying. Methods: We have explored the potential role of estrogens in this COVID-19 gendered impact. Results: Estrogens stimulate the humoral response to viral infections, while testosterone and progesterone give an immune suppression of both innate and cell-mediated immune responses. We hypothesise that estrogens, in particular estradiol but also synthetic estrogen such as ethinylestradiol, could protect women from the most serious complications of COVID-19. The use of medications that keep hormonal levels high and stable, such as combined hormonal contraceptive, could therefore play a protective role. These potential benefits overtake the thrombotic risk in healthy women. As stated by the World Health Organization, all modern methods of contraception were safe to use during the COVID-19 pandemic."],"journal":"Eur J Contracept Reprod Health Care","authors":["Grandi, Giovanni","Facchinetti, Fabio","Bitzer, Johannes"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32469251","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/13625187.2020.1766017","keywords":["androgen","covid-19","combined hormonal contraception","estradiol","estrogen","postmenopausal hormone therapy","progesterone; testosterone"],"locations":["estradiol"],"e_drugs":["Estradiol","Progesterone","Ethinyl Estradiol","Testosterone"],"topics":["Prevention","Mechanism"],"weight":1,"_version_":1668420887325442048,"score":235.7442},{"pmid":32331343,"title":"Sex-Specific SARS-CoV-2 Mortality: Among Hormone-Modulated ACE2 Expression, Risk of Venous Thromboembolism and Hypovitaminosis D.","text":["Sex-Specific SARS-CoV-2 Mortality: Among Hormone-Modulated ACE2 Expression, Risk of Venous Thromboembolism and Hypovitaminosis D.","Severe acute respiratory syndrome coronavirus (SARS-CoV-2) disease (COVID-19) appears to have a higher mortality rate in presence of comorbidities and in men. The latter suggests the presence of a possible sex-dependent susceptibility. An enzymatic system involved in this different predisposition could be represented by angiotensin converting enzyme 2 (ACE2). ACE2 is activated and down-regulated by the spike protein of the virus and allows the penetration of SARS-CoV-2 into epithelial cells and myocardium. Data on the experimental animal have shown that 17ss-estradiol increases the expression and activity of ACE2 in both adipose tissue and kidney. Spontaneously hypertensive male mice have a higher myocardial ACE2 expression than females and its levels decrease after orchiectomy. In addition to this first aspect, the recent evidence of an increased frequency of venous thromboembolism in patients with COVID-19 (a clinical element associated with a worse prognosis) calls the attention on the safety of treatment with testosterone, in particular in hypogonadal men with greater genetic predisposition. Evidence that sex hormones are able to modulate the expression of ACE2 could help in interpreting epidemiological results and in designing more appropriate intervention strategies. Moreover, the vitamin D deficiency in elderly men may be worthy of further study regarding the epidemiological aspects of this different susceptibility and lethality between sexes.","Int J Mol Sci","La Vignera, Sandro","Cannarella, Rossella","Condorelli, Rosita A","Torre, Francesco","Aversa, Antonio","Calogero, Aldo E","32331343"],"abstract":["Severe acute respiratory syndrome coronavirus (SARS-CoV-2) disease (COVID-19) appears to have a higher mortality rate in presence of comorbidities and in men. The latter suggests the presence of a possible sex-dependent susceptibility. An enzymatic system involved in this different predisposition could be represented by angiotensin converting enzyme 2 (ACE2). ACE2 is activated and down-regulated by the spike protein of the virus and allows the penetration of SARS-CoV-2 into epithelial cells and myocardium. Data on the experimental animal have shown that 17ss-estradiol increases the expression and activity of ACE2 in both adipose tissue and kidney. Spontaneously hypertensive male mice have a higher myocardial ACE2 expression than females and its levels decrease after orchiectomy. In addition to this first aspect, the recent evidence of an increased frequency of venous thromboembolism in patients with COVID-19 (a clinical element associated with a worse prognosis) calls the attention on the safety of treatment with testosterone, in particular in hypogonadal men with greater genetic predisposition. Evidence that sex hormones are able to modulate the expression of ACE2 could help in interpreting epidemiological results and in designing more appropriate intervention strategies. Moreover, the vitamin D deficiency in elderly men may be worthy of further study regarding the epidemiological aspects of this different susceptibility and lethality between sexes."],"journal":"Int J Mol Sci","authors":["La Vignera, Sandro","Cannarella, Rossella","Condorelli, Rosita A","Torre, Francesco","Aversa, Antonio","Calogero, Aldo E"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32331343","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.3390/ijms21082948","keywords":["ace2: venous thromboembolism","covid-19","sars-cov2","gender differences","vitamin d deficiency"],"e_drugs":["Vitamin D","Testosterone"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493981556740,"score":178.24231},{"pmid":32327870,"pmcid":"PMC7176384","title":"[Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology].","text":["[Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology].","The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy.","Rev Esp Cardiol","Vivas, David","Roldan, Vanessa","Esteve-Pastor, Maria Asuncion","Roldan, Inmaculada","Tello-Montoliu, Antonio","Ruiz-Nodar, Juan Miguel","Cosin-Sales, Juan","Maria Gamez, Jose","Consuegra, Luciano","Luis Ferreiro, Jose","Marin, Francisco","Arrarte, Vicente","Anguita, Manuel","Cequier, Angel","Perez-Villacastin, Julian","32327870"],"abstract":["The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy."],"journal":"Rev Esp Cardiol","authors":["Vivas, David","Roldan, Vanessa","Esteve-Pastor, Maria Asuncion","Roldan, Inmaculada","Tello-Montoliu, Antonio","Ruiz-Nodar, Juan Miguel","Cosin-Sales, Juan","Maria Gamez, Jose","Consuegra, Luciano","Luis Ferreiro, Jose","Marin, Francisco","Arrarte, Vicente","Anguita, Manuel","Cequier, Angel","Perez-Villacastin, Julian"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327870","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.recesp.2020.04.006","keywords":["antithrombotics","covid-19","covid-19, coronavirus infectious disease-19","coronavirus","doac, direct action oral anticoagulant","lmwh, low-molecular-weight heparin","sars-cov-2","sars-cov-2, severe acute respiratory syndrome coronavirus-2","thrombosis","vka, vitamin k antagonist","vted, venous thromboembolic disease"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1666138494596022272,"score":170.96097},{"pmid":32302462,"title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment.","text":["ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment.","We read with interest the International Society on Thrombosis and Hemostasis interim guidance on recognition and management of coagulopathy in COVID-19 (1). We applaud this group's efforts in releasing a timely article on the pandemic impacting all regions of the globe. While we agree that this interim guidance addresses important considerations for monitoring the disease process, we believe that the proposed treatment strategy of prophylactic low molecular weight heparin (LMWH) to treat severe COVID-19 coagulopathy is an unconvincing strategy. Patients that are critically ill with COVID-19 have hallmark signs of disseminated intravascular coagulation (DIC)(2), and as noted in the ISTH interim guidance and our own clinical practice, thrombosis is the overwhelming phenotype with rare bleeding complications. We address this concern with the existing data on the severe hypercoagulable state of COVID-19 victims and advocate for consideration of systemic anticoagulation with unfractionated heparin to prevent life threatening micro- and macrovascular thrombosis to mitigate their associated consequences, up to and including progression of respiratory and organ failure.","J Thromb Haemost","Barrett, Christopher D","Moore, Hunter B","Yaffe, Michael B","Moore, Ernest E","32302462"],"abstract":["We read with interest the International Society on Thrombosis and Hemostasis interim guidance on recognition and management of coagulopathy in COVID-19 (1). We applaud this group's efforts in releasing a timely article on the pandemic impacting all regions of the globe. While we agree that this interim guidance addresses important considerations for monitoring the disease process, we believe that the proposed treatment strategy of prophylactic low molecular weight heparin (LMWH) to treat severe COVID-19 coagulopathy is an unconvincing strategy. Patients that are critically ill with COVID-19 have hallmark signs of disseminated intravascular coagulation (DIC)(2), and as noted in the ISTH interim guidance and our own clinical practice, thrombosis is the overwhelming phenotype with rare bleeding complications. We address this concern with the existing data on the severe hypercoagulable state of COVID-19 victims and advocate for consideration of systemic anticoagulation with unfractionated heparin to prevent life threatening micro- and macrovascular thrombosis to mitigate their associated consequences, up to and including progression of respiratory and organ failure."],"journal":"J Thromb Haemost","authors":["Barrett, Christopher D","Moore, Hunter B","Yaffe, Michael B","Moore, Ernest E"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302462","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14860","keywords":["acute respiratory distress syndrome (ards)","anticoagulation","covid-19","disseminated intravascular coagulation","international society on thrombosis and haemostasis (isth)"],"locations":["ISTH"],"e_drugs":["Heparin, Low-Molecular-Weight","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666138494868652033,"score":163.98604}]}